

Minutes for the Institutional Biosafety Committee Meeting

Tuesday, August 12, 2025

Google Online Meeting

1:00 pm - 2:00 pm

Committee Members Present:

Dr. Robert Marr, Mr. Nikolas Vistine, Mr. Paul Huber, Mr. Sebastian Rodriguez, Dr. Joseph Reynolds, Dr. Patricia Loomis, Dr. David Everly, Dr. Fabio Re, Ms. Jacquelyn Casler and Dr. William Conrad

Committee Members Absent:

Mr. Matthew Anagnostopoulos
(left meeting early due to lack of electronic connection to the meeting)

Public Members Present:

There were no requests from the public to attend this meeting

Call to Order

The meeting called to order:

Dr. Robert Marr called the Institutional Biosafety Committee meeting to order at 1:04 pm with a quorum of committee members present.

Review of previous IBC Meeting Minutes

The IBC Committee reviewed the following Institutional Biosafety Meeting Minutes:

- July 8, 2025 meeting minutes were reviewed by the IBC members.

Dr. Robert Marr recommended a motion for the IBC members to approve the July 8, 2025 meeting minutes as written.

Motion to approve the July 8, 2025 meeting minutes:

First motion: Dr. Joseph Reynolds

Second motion: Dr. William Conrad

The IBC members unanimously approved the July 8, 2025 meeting minutes as written. Exceptions from voting on this approval of meeting minutes are Ms Jacquelyn Casler and Dr. William Conrad who was not present at the last IBC meeting.

New Business

The IBC committee reviewed and discussed the lab specific protocols from UP Oncolytics submitted by Dr. Parvez Akhtar

- Dr. Akhtar's recombinant DNA lab specific protocol was reviewed by the committee members. Dr. Akhtar is from an outside company, UP Oncolytics, who is working at Rosalind Franklin University. Upon discussion of the biosafety levels, Dr. Patricia Loomis agreed to revise the Recombinant/Synthetic Nucleic Acid Molecules Lab Protocol form for future protocol submittals. The wording is not clear on the form for levels one and two. Dr. Loomis stated she will revise the protocol form to make it more clear for future use.

Dr. Robert Marr recommended a motion for the committee to approve the recombinant DNA protocol as originally written.

First Motion: Dr. Patricia Loomis

Second Motion: Mr. Nikolas Vistine

The committee unanimously agreed to approve the recombinant DNA lab specific protocol as originally written with no significant changes or updates needed.

- **Revised Pathogenic Agent protocol**

Dr. Marr brought to the committee's attention that the information that is in the significant change is included in the recombinant protocol and this change is not needed since the information is sufficiently covered under the recombinant DNA protocol. Dr. Marr asked if any committee member felt differently about this decision. By a show of electronic voting, none of the committee members felt the significant change was necessary. The committee unanimously agreed to leave the pathogenic protocol as originally written.

A formal vote is not needed since the significant change to his pathogenic agent protocol is not needed.

Old Business

Final Review of Dr. Sean Schrank's Lab-Specific Protocol

- Dr. Marr confirmed that all recommended changes from the IBC committee were made to Dr. Schrank's lab-specific protocol prior to final approval.
- Dr. Marr reviewed the changes with the committee and verified that all revisions are appropriately incorporated into the final version of the protocol.

Other Business

There were no other business agenda topics for discussion.

Adjourn

With there being no further business to discuss, Dr. Marr recommended a motion to adjourn the meeting at 1:21 pm. The IBC committee unanimously approved the adjournment of the meeting.